**BRIEF REPORT** 



# Hand hygiene for prevention and control of viral infections: the role of Amuchina Gel Xgerm

Claudio Cermelli<sup>1</sup>, Elisabetta Blasi<sup>1</sup>, Alessandra Capezzone de Joannon<sup>2</sup>, Maria Ilaria Roselli<sup>3</sup>, Daniele Frollano<sup>3</sup>, Michela Procaccini<sup>3</sup>

<sup>1</sup>Department of Surgical, Medical, Dental and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena - Italy

<sup>2</sup>Global R&D Angelini Pharma S.p.A, Ancona - Italy

<sup>3</sup>Angelini Pharma S.p.A, Rome - Italy

#### ABSTRACT

**Introduction**: Alcohol-based hand sanitizers are used in healthcare settings, but their efficacy against both enveloped and non-enveloped viruses requires further investigation.

**Methods**: In this study, viral suspensions composed by the test virus, an interfering substance, and the test product, were exposed to Amuchina Gel Xgerm (100 g of the product contains 74 g of ethanol 96%; Angelini Pharma S.p.A) at 80% dilution in water, according to the European Standard EN14476:2013+A2:2019 – quantitative suspension test for the evaluation of virucidal activity in the medical area – for chemical disinfectants and antiseptics, in the presence of bovine serum albumin 0.3 g/L. The residual viral titers were measured.

**Results:** Sixty second exposures to the product determined a  $\geq 4 \log_{10}$  reduction of virus titer in all cases. For adenovirus type 5, human coxsakievirus, herpesvirus 1 and influenza virus A H1N1, a  $\geq 4 \log_{10}$  reduction of virus titer was obtained already after 30 s. Amuchina Gel Xgerm demonstrated effectiveness against seven virus families, including both enveloped and non-enveloped viruses.

**Conclusion:** Amuchina Gel Xgerm is a preventive measure against infection spread in healthcare and community settings, contributing to improved healthcare management.

Keywords: Alcohol-based hand sanitizer, Enveloped virus, Infection prevention, Non-enveloped virus

## Introduction

The transmission of infectious agents via contaminated objects (fomites) such as surfaces and hands is a significant concern in public health. Fomites play a well-documented role in the spread of viral infections in both healthcare settings and the community (1). Fomites contribute to the transmission of pathogens such as Enteroviruses, Rotaviruses, and Adenoviruses (2). Respiratory viruses, such as Influenza, Respiratory Syncytial Virus, and human Coronaviruses, can persist on fomites and the skin for periods of time up to a few days, facilitating transmission within the community (3).

Virus spreading is facilitated in contexts of overcrowding, social interaction, and close contact (2,3). Healthcare settings are central environments for viral transmission. Hospital

Received: December 13, 2024 Accepted: December 29, 2024 Published online: January 22, 2025

**Corresponding author:** Claudio Cermelli email: claudio.cermelli@unimore.it common areas such as waiting rooms, restrooms, and elevators are particularly critical points, due to the large number of individuals passing through them daily; even when standard, methodical cleaning techniques are applied, it is challenging to keep such areas (especially door handles, surfaces, etc.) appropriately sanified and safe (4).

Cross-infections (such as patient-to-patient, personnelto-patient, visitor-to-patient) co-acquired in healthcare environments can have serious consequences, given the high prevalence of vulnerable people, including elderly and immunocompromised subjects. In such environments, prevention of pathogen transmission remains the most efficient strategy, also considering the wide spread of (multi)drug resistant bacterial pathogens (5).

Viral pathogen transmission is highly likely in nurseries and schools due to close contact among children and inadequate hand and personal hygiene practices. The frequent social activities inside and outside schools may further favor overcrowding and microbial transmission (2,3). In addition, children are commonly a relevant unconscious vehicle of infectious agents toward vulnerable members of their families, further expanding the challenges in healthcare management. In these contexts, implementing effective infection prevention measures is crucial.

AboutOpen - ISSN 2465-2628 - www.aboutscience.eu/aboutopen

© 2024 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (<u>CC BY-NC 4.0</u>). Commercial use is not permitted and is subject to Publisher's permissions. Full information is available at <u>www.aboutscience.eu</u>

Extensive literature documents that prevention of viral transmission is essential in all seasons. In temperate regions, the transmission of most respiratory viruses peaks during winter, when overcrowding and close contacts increase, given the time spent indoors. In contrast, some viruses, such as Adenoviruses, are transmitted throughout the year, whereas others, like non-rhinovirus Enteroviruses, may even peak during the summer months (6).

Emphasizing the central role of surface disinfection and proper hand hygiene is essential for significantly reducing the risk of viral infections and to control disease spreading (7). Indeed, it has been shown that children attending daycare centers experienced fewer respiratory and gastrointestinal issues when surfaces, such as the school buses and toys, are routinely disinfected (7). Accordingly, hygiene measures that are easy to implement, even in the absence of water and soap, are expected to significantly increase infection control with respect to viruses and other pathogens.

Ethanol at a concentration of 70–80% (v/v) is effective against various enveloped viruses, including SARS and MERS Coronaviruses, human and avian Influenza viruses, Human Herpesvirus 1 and 2, and Respiratory Syncytial Viruses (8). Ethanol is essential in hand sanitizers (rubs, gels, foams) in healthcare settings, and is listed by the WHO as an essential medicine, recommended at 80% (v/v) concentration. Due to its activity also against non-enveloped viruses, ethanol is a critical virucidal agent in hand antisepsis (9). Experimental studies using contaminated thumb- and fingertip pads demonstrated that samples exposed to ethanol gel (60%) showed significantly lower levels of virus infectivity compared to control samples. As a matter of fact, the infectivity titers were reduced by 3 to >4  $\log_{10}$  when compared to a reduction of  $\leq 1 \log_{10}$  for the hard-water rinse (10).

Alcohol-based hand sanitizers are commonly used in hospital settings for hand hygiene, ensuring rapid, consistent, and effective disinfection. Their portability, ease of use, and widespread availability have made them popular among the general population. One of these products, the gel rub Amuchina Gel Xgerm (100 g of the product contains 74 g of ethanol 96%; Angelini Pharma S.p.A), is already certified as a disinfectant and antiseptic agent. This sanitizer has been shown to efficiently reduce SARS-CoV-2 virus titers below detectable limits (≥4 log10 reduction of viral recovery) after 30 and 60 seconds exposures, as assessed by standard suspension tests (11). Given the widespread use of hand sanitizers and their significant impact on public health for prevention of viral spreading, an in-depth knowledge about the spectrum of their virucidal efficacy is crucial to implement their usage in a variety of settings, particularly those housing vulnerable people or where viral agents transmission is more likely to occur.

The present study aimed to establish *in vitro* the virucidal activity of Amuchina Gel Xgerm against a panel of enveloped and non-enveloped human viruses.

## Materials and methods

The virucidal activity tests were performed according to the European Standard EN14476:2013+A2:2019 (12); the product was assessed at a final concentration of 80% (8ml of the product + 1 ml of viral suspension + 1 ml of interfering substance), in the presence of 0.3 g/L of bovine serum albumin as interfering substance – an organic material that might be present in environments where the virucidal agent is used, mimicking real-world conditions -(12), for either 30 or 60 s, at 20°C ±1°C. The non-enveloped viruses tested included Adenovirus type 5, Rotavirus A, and human Coxsakievirus B5. The enveloped viruses included Influenza A (H3N2 and H1N1), Respiratory Syncytial Virus, and human Herpesvirus 1. After exposure time, the test mixture was filtered using MicrospinTM S 400 HR columns and then subjected to the following procedures: a) eight 10-fold serial dilutions with a cold Minimum Essential Medium Eagle (MEM) + 2% fetal calf serum (FCS) were set up, each incubated with cells at 37°C for 5-7 days to quantify the cytopathic effect; b) if the product showed residual cytotoxicity on the cell line at the tested concentrations, then the large volume plating (LVP) method was used instead, at 80% concentration. The 50% tissue culture infectious dose (TCID<sub>50</sub>) per ml value was calculated by the Spearman–Karber method and converted to log<sub>10</sub> of TCID<sub>50</sub> (11). All the tests were performed with the appropriate controls in accordance with the European Standard EN14476:2013+A2:2019 (12).

#### Results

The viral strains tested, the TCID<sub>50</sub> viral load recovery values, and the corresponding reduction after exposure to Amuchina Gel Xgerm are shown in Table I. As established by the European Protocol (12), viral titer reduction values  $\geq 4$ log<sub>10</sub> denote a complete inactivation of the virus. For all the tested viral pathogens, a 60 s treatment with the sanitizer reduced viral titers to undetectable levels, achieving a  $\geq 4 \log_{10}$ reduction in viral recovery (Table I). In particular, a  $\geq 4 \log_{10}$ reduction was observed already after 30 s of exposure when the product was tested against Coxsakievirus B5, Influenza virus (H1N1), Adenovirus type 5, and human Herpesvirus 1. The data from this study that the Amuchina Gel Xgerm passed the virucidal efficacy suspension test, for both enveloped and non-enveloped pathogens. These findings are in line with recent results observed against SARS-CoV-2 (11). The virucidal effects of Amuchina Gel Xgerm against non-enveloped viruses deserve special consideration, since such viruses are known to be significantly less susceptible to ethanol than the enveloped ones (13). The control test results are shown in Table II: all the controls resulted valid.

#### Discussion

The present data support the notion that the use of hand sanitizers may effectively disrupt the virus transmission chain, thereby reducing the risk of potential disease spread in different contexts, including hospital and healthcare settings, public institutions such as schools, and social gatherings like parties, concerts and summer camps. Amuchina Gel Xgerm is easy to use, making it an effective alternative when soap and water are not immediately available, providing sanitization against a broad range of viral particles (6).

The preventive use of hand sanitizers not only represents a first line of defense against the initial infection but also

| TABLE 1 | - Viral     | load | before | and | after | Amuchina | Gel | Xgerm | treatment |
|---------|-------------|------|--------|-----|-------|----------|-----|-------|-----------|
|         | • • • • • • |      |        | ~   |       | ,        | ~~. |       |           |

| Type of infection caused  | Virus [strain]                                                         | Exposure<br>time (s) | Input load virus<br>titer (log <sub>10</sub> TCID <sub>50</sub> ) | Ouput load virus<br>titer (log <sub>10</sub> TCID <sub>50</sub> ) | Reduction<br>(log <sub>10</sub> TCID <sub>50</sub> ) |  |  |  |
|---------------------------|------------------------------------------------------------------------|----------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|------------------------------------------------------|--|--|--|
| Non-enveloped             |                                                                        |                      |                                                                   |                                                                   |                                                      |  |  |  |
| Respiratory<br>infections | Adenovirus type 5                                                      | 30                   | 6.63 ± 0.00                                                       | 2.5 ± 0.00                                                        | $> 4.00 \pm 0.00$                                    |  |  |  |
|                           | [Adenoid, 75 ATCC VR-5]                                                |                      |                                                                   |                                                                   |                                                      |  |  |  |
| Other infections          | Rotavirus A                                                            | 60                   | 6.17 ± 0.40                                                       | ≤ 1.33 ± 0.00                                                     | ≥ 5.50 ± 0.40                                        |  |  |  |
|                           | [HumanG8P10, RVB-1221 FLI]                                             |                      |                                                                   |                                                                   |                                                      |  |  |  |
|                           | Human Coxsackievirus B5                                                | 30                   | 5.50 ± 0.00                                                       | ≤ 1.03 ± 0.00                                                     | ≥ 5.47 ± 0.00                                        |  |  |  |
|                           | [ATCC VR-185]                                                          |                      |                                                                   |                                                                   |                                                      |  |  |  |
| Enveloped                 |                                                                        |                      |                                                                   |                                                                   |                                                      |  |  |  |
| Respiratory<br>infections | Influenza A/swine/lowa/15/30 virus (H1N1)<br>[ATCC-VR-1683]            | 30                   | 6.63 ± 0.00                                                       | 2.50 ± 0.00                                                       | > 4.00 ± 0.00                                        |  |  |  |
|                           | Influenza A/Hong Kong/8/68 virus, (H3N2), TC<br>adapted [ATCC VR-1679] | 60                   | $6.50 \pm 0.00$                                                   | ≤ 1.03 ±0.00                                                      | ≥ 5.47 ± 0.00                                        |  |  |  |
|                           | Human Respiratory Syncytial Virus [ATCC VR-26]                         | 60                   | $4.50 \pm 0.00$                                                   | ≤ 1.33 ± 0.00                                                     | ≥ 4.17 ± 0.00                                        |  |  |  |
| Other infections          | Human Herpesvirus 1<br>[ATCC VR-733]                                   | 30                   | 7.50 ± 0.00                                                       | ≤ 3.50 ± 0.00                                                     | ≥ 4.00 ± 0.00                                        |  |  |  |

 $TDID_{50}$  was calculated using Spearman - Kaber method:  $TDI_{50} = V - [(S/100-0.5) \times D]$ , where: V = negative log of the highest virus concentration tested; S = sum of the % affected wells at each concentration; D = log of dilution.

The indicated values are the mean ± standard error of 6 replicate samples.

#### TABLE 2 - Results of the control assays, performed according to the EU protocol

|                           |                                                                 |                           |                       |        |                                | Cell susceptibility                 |         | Efficacy of suppression                 |         |
|---------------------------|-----------------------------------------------------------------|---------------------------|-----------------------|--------|--------------------------------|-------------------------------------|---------|-----------------------------------------|---------|
| Type of                   | Virus [strain]                                                  | Cel line                  | Test                  | Sample | Virus titer <sup>#</sup>       | Virus titer <sup>#</sup>            | Result* | Virus titer <sup>#</sup>                | Result* |
| infection                 |                                                                 | [source]                  | method                |        | $\log_{10} \mathrm{TCID}_{50}$ | $\log_{_{10}}\mathrm{TCID}_{_{50}}$ |         | $\log_{10} \mathrm{TCID}_{\mathrm{50}}$ |         |
| Non-enveloped             |                                                                 |                           |                       |        |                                |                                     |         |                                         |         |
| Respiratory<br>infections | Adenovirus type 5                                               | HeLa                      | Filtration            | 80%    | 6.63 ± 0.00                    | $6.89 \pm 0.00$                     | 0.00    | $6.38 \pm 0.00$                         | 0.13    |
|                           | [Adenoid, 75 ATCC VR-5]                                         | [ATCC CCL-2]              |                       | PBS    |                                | $6.89 \pm 0.00$                     | _       | -                                       | -       |
| Other<br>infections       | Rotavirus A                                                     | MA-104                    | Filtration            | 80%    | 6.17 ± 0.40                    | $6.00 \pm 0.45$                     | 0.33    | 5.67 ± 0.35                             | 0.50    |
|                           | [HumanG8P10, RVB-1221<br>FLI]                                   | [CCLV-RIE 142]            | and LVP               | PBS    |                                | 6.33 ± 0.35                         | _       | _                                       |         |
|                           | Human Coxsackievirus B5                                         | LLC-MK2                   | Filtration<br>and LVP | 80%    | 5.50 ± 0.00                    | 5.33 ± 0.35                         | 0.33    | 5.33 ± 0.35                             | 0.17    |
|                           | [ATCC VR-185]                                                   | [CCLV-RIE 1418]           |                       | PBS    |                                | 5.67 ± 0.35                         | _       | -                                       | -       |
| Enveloped                 |                                                                 |                           |                       |        |                                |                                     |         |                                         |         |
| Respiratory<br>infections | Influenza A/swine/<br>lowa/15/30 virus (H1N1)<br>[ATCC-VR-1683] | LLC-MK2<br>[ATCC CCL-7.1] | Filtration            | 80%    | 6.63 ± 0.00                    | $6.00 \pm 0.00$                     | 0.625   | $6.50 \pm 0.00$                         | 0.00    |
|                           |                                                                 |                           |                       | PBS    |                                | 6.63 ± 0.00                         | -       | -                                       | -       |
|                           | Influenza A/Hong                                                | MDCK<br>[ATCC CCL-34]     | LVP                   | 80%    | 6.50 ± 0.00                    | $6.50\pm0.00$                       | 0.83    | $6.00 \pm 0.45$                         | 0.50    |
|                           | Kong/8/68 virus (H3N2), TC<br>adapted [ATCC VR-1679]            |                           |                       | PBS    |                                | 7.33 ± 0.35                         | _       | _                                       | _       |
|                           | Human Respiratory                                               | Hep-2                     | Filtration            | 80%    | 4.50 ± 0.00                    | 4.33 ± 0.35                         | 0.17    | $4.17\pm0.40$                           | 0.33    |
|                           | Syncytial Virus [ATCC VR-26]                                    | [ATCC CCL-23]             | and LVP               | PBS    |                                | $4.50 \pm 0.00$                     | -       | _                                       | _       |
| Other<br>infections       | Human Herpesvirus 1                                             | VERO                      | Filtration            | 80%    | 7.50 ± 0.00                    | 7.17 ± 0.40                         | 0.50    | 7.33 ± 0.37                             | 0.17    |
|                           | [ATCC VR-733]                                                   | [ATCC CCL-81]             | FILLATION             | PBS    |                                | 7.67 ± 0.35                         | -       | -                                       | -       |

\* Mean ± standard error of 6 replicate samples.

\*Viral interference control ( $\log_{10}$  titer difference): test is acceptable if the titer difference between the neutralized test product-treated and PBS-treated cellular monolayers is  $\leq$ 1.0  $\log_{10}$  in the viral interference control.

PBS: Phosphate-buffered saline; TCID50: 50% tissue culture infective dose; LVP: large volume plating

plays a crucial role in mitigating the risk of multiple infections (14). Vulnerable and immunocompromised individuals face an increased risk of severe outcomes, especially when concomitant infections may simultaneously occur, further complicating the initial illness (15,16). As a result, the clinical condition can deteriorate, making treatment and recovery more challenging.

Integrating hand hygiene practices into daily routines and public health strategies can be useful for protecting vulnerable populations and minimizing the overall impact of infectious diseases in our complex and dynamic society. Increasing awareness of the efficacy of the use of hand sanitizers through sensitizing campaigns will likely benefit the healthcare system, not only as reduced access of people to hospitals but also as overall saving costs for the healthcare system.

The hereabove demonstrated broad-spectrum virucidal activity of the alcohol-based hand sanitizer Amuchina Gel Xgerm, strongly supports its usage in environments where the risk of virus transmission is high, such as hospitals, schools, and public spaces. Different sets of investigations are needed to establish the efficacy of this gel against other pathogens, such as bacterial agents.

Amuchina Gel Xgerm has been assessed using an in vitro suspension assay, a standard method for testing virucidal activity, in accordance with European Standard EN14476:2013+A2:2019 criteria (12); interestingly, the products is effective, even in the presence of an interfering substance, such as bovine serum albumin, that, according to the standard European protocol (12), mimics the real conditions on the field. In fact, in the environment, viruses are typically agglomerated with proteins and other biomolecules that influence their interactions with host cells. The inclusion of BSA in viral suspensions helps create a real-world environment by providing a matrix that mimics the biological fluids encountered during actual infections. This can affect how viruses attach to and enter host cells, which is critical for understanding their pathogenicity. The observed wide spectrum efficacy underlines the relevance of hand sanitizer in many different situations when there is a risk of viral pathogens spreading via fomites.

#### Limitations

The main limitation of the present work is that being an *in vitro* study, it does not address the efficacy of the product in real-world settings; variability in user application techniques and adherence to hand hygiene recommendations, as well as environmental factors such as temperature and humidity, which can affect virus persistence on surfaces, have not been taken into account.

#### Conclusions

Amuchina Gel Xgerm hand sanitizer exerts a broad spectrum virucidal activity *in vitro*, being effective against both enveloped and non-enveloped viruses.

Promoting hand hygiene practices can limit the spreading of viral infections within the general population and enhance the protection of the most vulnerable individuals in clinical settings.

Given the epidemiological importance of the transmission of viral pathogens in hospitals and in the community, these findings underscore the potential impact of this alcoholbased formulation that will positively impact public health by reducing the transmission of infectious diseases.

#### Disclosures

**Financial support:** Writing and editing assistance was provided by Health Publishing and Services Srl, with the helpful support of Corrado Minetti, PhD, and supported by an unconditioned grant from Angelini Pharma.

**Conflict of interest:** ACdJ, MIR, DF, and MP are full-time employees of Angelini Pharma S.p.A. CC and EB have nothing to disclose.

**Author contribution:** ACdJ, MIR, DF, and MP: conception of the work, acquisition, analysis, interpretation of data for the work; drafting the work and revising it critically. CC and EB: interpretation of data for the work; drafting the work and revising it critically for important intellectual content. All authors approved the final version of the manuscript submitted and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Data availability statement:** The data that support the findings of this study are available from the corresponding author, CC, upon reasonable request.

### References

- Stephens B, Azimi P, Thoemmes MS, Heidarinejad M, Allen JG, Gilbert JA. Microbial Exchange via Fomites and Implications for Human Health. Curr Pollut Rep. 2019;5(4):198-213. <u>CrossRef</u> <u>PubMed</u>
- Bányai K, Estes MK, Martella V, Parashar UD. Viral gastroenteritis. Lancet. 2018;392(10142):175-186. CrossRef PubMed
- Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol. 2021;19(8):528-545. <u>CrossRef</u> <u>PubMed</u>
- Cunningham B, O'Neill V, Devereux M, McGann D, O'Hora J. Use of a door handle disinfection system to reduce the risks associated with microbial loads on fomites in a healthcare setting. J Hosp Infect. 2022;130:104-107. <u>CrossRef PubMed</u>
- Christaki E, Marcou M, Tofarides A. Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence. J Mol Evol. 2020;88(1):26-40. <u>CrossRef PubMed</u>
- Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. Annu Rev Virol. 2020;7(1):83-101. CrossRef PubMed
- Boone SA, Gerba CP. Significance of fomites in the spread of respiratory and enteric viral disease. Appl Environ Microbiol. 2007;73(6):1687-1696. <u>CrossRef PubMed</u>
- Kampf G. Efficacy of ethanol against viruses in hand disinfection. J Hosp Infect. 2018;98(4):331-338. <u>CrossRef PubMed</u>
- Kramer A, Arvand M, Christiansen B, et al. Ethanol is indispensable for virucidal hand antisepsis: memorandum from the alcohol-based hand rub (ABHR) Task Force, WHO Collaborating Centre on Patient Safety, and the Commission for Hospital Hygiene and Infection Prevention (KRINKO), Robert Koch Institute, Berlin, Germany. Antimicrob Resist Infect Control. 2022;11(1):93. CrossRef PubMed
- Sattar SA, Abebe M, Bueti AJ, Jampani H, Newman J, Hua S. Activity of an alcohol-based hand gel against human adeno-,

rhino-, and rotaviruses using the fingerpad method. Infect Control Hosp Epidemiol. 2000;21(8):516-519. CrossRef PubMed

- de Joannon AC, Testa A, Falsetto N, Procaccini M, Ragni L. Amuchina Gel Xgerm hand rub in vitro virucidal activity against SARS-CoV-2. Future Microbiol. 2021;16(11):797-800. <u>CrossRef</u> <u>PubMed</u>
- 12. EuropeanStandards. EN 14476:2013+A2:2019 Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of virucidal activity in the medical area. Test method and requirements (Phase 2/Step 1) n.d. <u>Online</u> (Accessed December 2024)
- 13. Anderson CE, Tong J, Zambrana W, B Boehm A, K Wolfe M. Investigating the Efficacy of Various Handwashing Methods

against Enveloped and Non-Enveloped Viruses. Am J Trop Med Hyg. 2023;108(4):820-828. <u>CrossRef PubMed</u>

- 14. Vuppu S, Mishra T, Chinamgari A. Use of Hand Sanitizers in COVID-19 Prevention: A Comprehensive Overview. Pharmacoepidemiology. 2023;2(3):257-271. <u>CrossRef</u>
- Devi P, Khan A, Chattopadhyay P, et al. Co-infections as Modulators of Disease Outcome: Minor Players or Major Players? Front Microbiol. 2021;12:664386. CrossRef PubMed
- Agrati C, Bartolini B, Bordoni V, et al. Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response. Front Immunol. 2023;14:1147871. <u>CrossRef PubMed</u>